Oxbryta Tablet, Film Coated
Product Images NDC 72786-102

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Oxbryta (NDC 72786-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Global Blood Therapeutics, Inc, A Subsidiary Of Pfizer Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Oxbryta 01)

Chemical Structure (Oxbryta 01)
FDA Label Image

Figure 1 (Oxbryta 02)

Figure 1 (Oxbryta 02)
FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Label)

Principal Display Panel (500 mg Tablet Bottle Label)
FDA Label Image

Oxbryta 04

Oxbryta 04
FDA Label Image

Oxbryta 05

Oxbryta 05
FDA Label Image

Oxbryta 06

Oxbryta 06
FDA Label Image

Oxbryta 07

Oxbryta 07
FDA Label Image

Oxbryta 08

Oxbryta 08
FDA Label Image

Oxbryta 09

Oxbryta 09
FDA Label Image

Oxbryta 10

Oxbryta 10
Oxbryta is a tablet medication with each tablet containing 500mg of voxelotor. It is vital to swallow the tablets whole and not to crush, cut or chew them. The dosage of Oxbryta should be referred to the prescribing information. The medication should be stored at 20°C to 30°C (68°F to 86°F) and should not be used if the safety seal under the cap is broken. This medication is manufactured and distributed by Global Blood Therapeutics.*
FDA Label Image

Oxbryta 11

Oxbryta 11
Reonly Oxbryta is a medication available in tablet form with each tablet containing 300mg of voxelotor. The tablets must be dissolved in clear liquid before ingestion and should not be chewed or swallowed whole. The recommended dosage is available in the prescribing information. It should be stored in a place with a temperature range of 20°C to 30°C (68°F to 86°F). The medication should not be used if the safety seal under the cap is broken or missing. Reonly Oxbryta is manufactured for Global Blood Therapeutics Inc. and is not suitable for children. NDC 72786-111-03 and GTIN 00372786111035 are the identification codes for the medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.